{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:19:14Z","timestamp":1791908354080,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"High Level Public Health Technology Talent Construction Project","award":["DL-02-21"],"award-info":[{"award-number":["DL-02-21"]}]},{"name":"Reform and Development Program of Beijing Institute of Respiratory Medicine","award":["Ggyfz202321"],"award-info":[{"award-number":["Ggyfz202321"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management. We aimed to identify associations between clinical characteristics and outcomes in patients with F-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospectively, 575 out of 926 patients with F-ILD were eligible for analysis. Four clusters were identified based on baseline data using cluster analysis. The clinical characteristics and outcomes were compared among the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cluster 1 was characterized by a high prevalence of comorbidities and hypoxemia at rest, with the worst lung function at baseline; Cluster 2 by young female patients with less or no smoking history; Cluster 3 by male patients with highest smoking history, the most noticeable signs of velcro crackles and clubbing of fingers, and the severe lung involvement on chest image; Cluster 4 by male patients with a high percentage of occupational or environmental exposure. Clusters 1 (median overall survival [OS]\u2009=\u20097.0 years) and 3 (OS\u2009=\u20095.9 years) had shorter OS than Clusters 2 (OS\u2009=\u2009not reached, Cluster 1: p\u2009&lt;\u20090.001, Cluster 3: p\u2009&lt;\u20090.001) and 4 (OS\u2009=\u2009not reached, Cluster 1: p\u2009=\u20090.004, Cluster 3: p\u2009&lt;\u20090.001). Clusters 1 and 3 had a higher cumulative incidence of acute exacerbation than Clusters 2 (Cluster 1: p\u2009&lt;\u20090.001, Cluster 3: p\u2009=\u20090.014) and 4 (Cluster 1: p\u2009&lt;\u20090.001, Cluster 3: p\u2009=\u20090.006). Stratification by using clusters also independently predicted acute exacerbation (p\u2009&lt;\u20090.001) and overall survival (p\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The high degree of disease heterogeneity of F-ILD can be underscored by four clusters based on clinical characteristics, which may be helpful in predicting the risk of fibrosis progression, acute exacerbation and overall survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02735-7","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:02:07Z","timestamp":1698843727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cluster features in fibrosing interstitial lung disease and associations with prognosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuanying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"150","key":"2735_CR1","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung Diseases. Eur Respir Rev. 2018;27(150):180076.","journal-title":"Eur Respir Rev"},{"issue":"5","key":"2735_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/MCP.0000000000000712","volume":"26","author":"A Wongkarnjana","year":"2020","unstructured":"Wongkarnjana A, Scallan C, Kolb MRJ. Progressive fibrosing interstitial lung Disease: treatable traits and therapeutic strategies. Curr Opin Pulm Med. 2020;26(5):436\u201342.","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"2735_CR3","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","volume":"57","author":"M Nasser","year":"2021","unstructured":"Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung Disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021;57(2):2002718.","journal-title":"Eur Respir J"},{"issue":"18","key":"2735_CR4","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing interstitial lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"2735_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung Disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925\u201334.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"2735_CR6","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an update) and Progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u2013e47.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2735_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12931-022-02094-7","volume":"23","author":"MC Schimmelpennink","year":"2022","unstructured":"Schimmelpennink MC, Meek DB, Vorselaars ADM, et al. Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis. Respir Res. 2022;23(1):169.","journal-title":"Respir Res"},{"issue":"2","key":"2735_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung Disease in patients with systemic sclerosis-associated interstitial lung Disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219\u201327.","journal-title":"Ann Rheum Dis"},{"issue":"150","key":"2735_CR9","doi-asserted-by":"publisher","first-page":"180073","DOI":"10.1183\/16000617.0073-2018","volume":"27","author":"SLF Walsh","year":"2018","unstructured":"Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung Diseases. Eur Respir Rev. 2018;27(150):180073.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"2735_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12859-022-04675-1","volume":"23","author":"ES Dalmaijer","year":"2022","unstructured":"Dalmaijer ES, Nord CL, Astle DE. Statistical power for cluster analysis. BMC Bioinformatics. 2022;23(1):205\u20135.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"2735_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.chest.2017.09.026","volume":"153","author":"A Adegunsoye","year":"2018","unstructured":"Adegunsoye A, Oldham JM, Chung JH, et al. Phenotypic clusters predict outcomes in a longitudinal interstitial lung Disease Cohort. Chest. 2018;153(2):349\u201360.","journal-title":"Chest"},{"issue":"5","key":"2735_CR12","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u2013e68.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2735_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"2735_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for Idiopathic Pulmonary Fibrosis. Ann Intern Med. 2012;156:684\u201391.","journal-title":"Ann Intern Med"},{"key":"2735_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung Disease: the ILD-GAP model. Chest. 2014;145:723\u20138.","journal-title":"Chest"},{"issue":"3","key":"2735_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al. Acute exacerbation of Idiopathic Pulmonary Fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2735_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/resp.13682","volume":"25","author":"A Suzuki","year":"2020","unstructured":"Suzuki A, Kondoh Y, Brown KK, et al. Acute exacerbations of fibrotic interstitial lung Diseases. Respirology. 2020;25(5):525\u201334.","journal-title":"Respirology"},{"issue":"2","key":"2735_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society\/European","year":"2002","unstructured":"American Thoracic Society\/European. Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2735_CR19","first-page":"e2021047","volume":"38","author":"Y Lia","year":"2022","unstructured":"Lia Y, Fana Y, Wanga Y, et al. Phenotypic clusters and survival analyses in interstitial Pneumonia with myositis-specific autoantibodies. Sarcoidosis Vasc Diffuse Lung Dis. 2022;38(4):e2021047.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"2735_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.55563\/clinexprheumatol\/t2hxjd","volume":"40","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xue Y, Liu X, et al. Identification of 4 subgroups in juvenile dermatomyositis by principal component analysis-based cluster analysis. Clin Exp Rheumatol. 2022;40(2):443\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"2735_CR21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1164\/rccm.201808-1543OC","volume":"199","author":"W Wu","year":"2019","unstructured":"Wu W, Bang S, Bleecker ER, et al. Multiview Cluster Analysis identifies variable corticosteroid response phenotypes in severe Asthma. Am J Respir Crit Care Med. 2019;199(11):1358\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"2735_CR22","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/COPD.S205517","volume":"14","author":"HY Yoon","year":"2019","unstructured":"Yoon HY, Park SY, Lee CH, et al. Prediction of first acute exacerbation using COPD subtypes identified by cluster analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:1389\u201397.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"2735_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.healun.2019.12.012","volume":"39","author":"R Badagliacca","year":"2020","unstructured":"Badagliacca R, Rischard F, Papa S, et al. Clinical implications of idiopathic pulmonary arterial Hypertension phenotypes defined by cluster analysis. J Heart Lung Transplant. 2020;39(4):310\u201320.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"2735_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12931-022-01993-z","volume":"23","author":"NW Lin","year":"2022","unstructured":"Lin NW, Arbet J, Mroz MM, et al. Clinical phenotyping in sarcoidosis using cluster analysis. Respir Res. 2022;23(1):88.","journal-title":"Respir Res"},{"key":"2735_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2020.05.023","volume":"80","author":"K Marks-Garber","year":"2020","unstructured":"Marks-Garber K, Bdolah-Abram T, Nusair S. Cluster analysis based clinical profiling of Idiopathic Pulmonary Fibrosis patients according to comorbidities evident prior to diagnosis: a single-center observational study. Eur J Intern Med. 2020;80:18\u201323.","journal-title":"Eur J Intern Med"},{"issue":"12","key":"2735_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2169\/internalmedicine.55.6009","volume":"55","author":"S Sato","year":"2016","unstructured":"Sato S, Tanino Y, Misa K, et al. Identification of clinical phenotypes in idiopathic interstitial Pneumonia with Pulmonary Emphysema. Intern Med. 2016;55(12):1529\u201335.","journal-title":"Intern Med"},{"issue":"5","key":"2735_CR27","first-page":"683","volume":"75","author":"KM O\u2019Reilly","year":"2007","unstructured":"O\u2019Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ. Asbestos-related lung Disease. Am Fam Physician. 2007;75(5):683\u20138.","journal-title":"Am Fam Physician"},{"issue":"11","key":"2735_CR28","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1111\/all.14202","volume":"75","author":"RF Hoy","year":"2020","unstructured":"Hoy RF, Chambers DC. Silica-related Diseases in the modern world. Allergy. 2020;75(11):2805\u201317.","journal-title":"Allergy"},{"issue":"8","key":"2735_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4239\/wjd.v11.i8.351","volume":"11","author":"V Rajasurya","year":"2020","unstructured":"Rajasurya V, Gunasekaran K, Surani S. Interstitial lung Disease and Diabetes. World J Diabetes. 2020;11(8):351\u20137.","journal-title":"World J Diabetes"},{"issue":"153","key":"2735_CR30","doi-asserted-by":"publisher","first-page":"190022","DOI":"10.1183\/16000617.0022-2019","volume":"28","author":"BF Collins","year":"2019","unstructured":"Collins BF, Raghu G. Antifibrotic therapy for fibrotic lung Disease beyond Idiopathic Pulmonary Fibrosis. Eur Respir Rev. 2019;28(153):190022.","journal-title":"Eur Respir Rev"},{"key":"2735_CR31","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.15420\/cfr.2021.30","volume":"8","author":"A Aimo","year":"2022","unstructured":"Aimo A, Spitaleri G, Nieri D, et al. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev. 2022;8:e12.","journal-title":"Card Fail Rev"},{"issue":"5","key":"2735_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with Progressive fibrotic interstitial lung Diseases other than Idiopathic Pulmonary Fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2735_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable Progressive fibrosing interstitial lung Disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147\u201357.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2735_CR34","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s12325-020-01384-0","volume":"37","author":"WA Wuyts","year":"2020","unstructured":"Wuyts WA, Papiris S, Manali E, et al. The Burden of Progressive Fibrosing interstitial lung Disease: a DELPHI Approach. Adv Ther. 2020;37(7):3246\u201364.","journal-title":"Adv Ther"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02735-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:02:26Z","timestamp":1698843746000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02735-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2735"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02735-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Beijing Chao-Yang Hospital (2020-KY-437) and performed by the principles of the Declaration of Helsinki. The requirement of obtaining informed consent was waived by the Ethics Committee of Beijing Chao-Yang Hospital due to the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"420"}}